Literature DB >> 32901521

Differential effects of the cystic fibrosis lung inflammatory environment on mesenchymal stromal cells.

Soraia C Abreu1,2, Thomas H Hampton3, Evan Hoffman1, Jacob Dearborn1, Alix Ashare3,4, Karatatiwant Singh Sidhu5, Dwight E Matthews1,5, David H McKenna6, Eyal Amiel7, Jayita Barua8, Anna Krasnodembskaya9, Karen English10, Bernard Mahon11, Claudia Dos Santos12, Fernanda F Cruz2,13, Daniel C Chambers14,15, Kathleen D Liu16, Michael A Matthay16, Robert A Cramer3, Bruce A Stanton3, Patricia R M Rocco2,13, Matthew J Wargo17, Daniel J Weiss1, Sara Rolandsson Enes1,18.   

Abstract

Growing evidence demonstrates that human mesenchymal stromal cells (MSCs) modify their in vivo anti-inflammatory actions depending on the specific inflammatory environment encountered. Understanding this better is crucial to refine MSC-based cell therapies for lung and other diseases. Using acute exacerbations of cystic fibrosis (CF) lung disease as a model, the effects of ex vivo MSC exposure to clinical bronchoalveolar lavage fluid (BALF) samples, as a surrogate for the in vivo clinical lung environment, on MSC viability, gene expression, secreted cytokines, and mitochondrial function were compared with effects of BALF collected from healthy volunteers. CF BALF samples that cultured positive for Aspergillus sp. (Asp) induced rapid MSC death, usually within several hours of exposure. Further analyses suggested the fungal toxin gliotoxin as a potential mediator contributing to CF BALF-induced MSC death. RNA sequencing analyses of MSCs exposed to either Asp+ or Asp- CF BALF samples identified a number of differentially expressed transcripts, including those involved in interferon signaling, antimicrobial gene expression, and cell death. Toxicity did not correlate with bacterial lung infections. These results suggest that the potential use of MSC-based cell therapies for CF or other lung diseases may not be warranted in the presence of Aspergillus.

Entities:  

Keywords:  Aspergillus infection; cell therapy; cystic fibrosis; gliotoxin; mesenchymal stromal cell

Mesh:

Substances:

Year:  2020        PMID: 32901521     DOI: 10.1152/ajplung.00218.2020

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  10 in total

1.  Sweat metabolomics before and after intravenous antibiotics for pulmonary exacerbation in people with cystic fibrosis.

Authors:  Frederick W Woodley; Emrah Gecili; Rhonda D Szczesniak; Chandra L Shrestha; Christopher J Nemastil; Benjamin T Kopp; Don Hayes
Journal:  Respir Med       Date:  2021-11-23       Impact factor: 3.415

Review 2.  Secondary Lymphoid Organs in Mesenchymal Stromal Cell Therapy: More Than Just a Filter.

Authors:  Di Zheng; Tejasvini Bhuvan; Natalie L Payne; Tracy S P Heng
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

3.  Effect of mesenchymal stromal cell infusions on lung function in COPD patients with high CRP levels.

Authors:  Daniel J Weiss; Karen Segal; Richard Casaburi; Jack Hayes; Donald Tashkin
Journal:  Respir Res       Date:  2021-05-08

4.  Healthy versus inflamed lung environments differentially affect mesenchymal stromal cells.

Authors:  Sara Rolandsson Enes; Thomas H Hampton; Jayita Barua; David H McKenna; Claudia C Dos Santos; Eyal Amiel; Alix Ashare; Kathleen D Liu; Anna D Krasnodembskaya; Karen English; Bruce A Stanton; Patricia R M Rocco; Michael A Matthay; Daniel J Weiss
Journal:  Eur Respir J       Date:  2021-10-14       Impact factor: 33.795

Review 5.  Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases.

Authors:  Sara Rolandsson Enes; Anna D Krasnodembskaya; Karen English; Claudia C Dos Santos; Daniel J Weiss
Journal:  Front Pharmacol       Date:  2021-04-19       Impact factor: 5.810

Review 6.  Mesenchymal stem/stromal cell-based therapies for severe viral pneumonia: therapeutic potential and challenges.

Authors:  C H Masterson; A Ceccato; A Artigas; C Dos Santos; P R Rocco; S Rolandsson Enes; D J Weiss; D McAuley; M A Matthay; K English; G F Curley; J G Laffey
Journal:  Intensive Care Med Exp       Date:  2021-12-31

Review 7.  The Inflammatory Lung Microenvironment; a Key Mediator in MSC Licensing.

Authors:  Hazel Dunbar; Daniel J Weiss; Sara Rolandsson Enes; John G Laffey; Karen English
Journal:  Cells       Date:  2021-11-02       Impact factor: 6.600

Review 8.  Promises and challenges of personalized medicine to guide ARDS therapy.

Authors:  Katherine D Wick; Daniel F McAuley; Joseph E Levitt; Jeremy R Beitler; Djillali Annane; Elisabeth D Riviello; Carolyn S Calfee; Michael A Matthay
Journal:  Crit Care       Date:  2021-11-23       Impact factor: 19.334

Review 9.  Harnessing the ECM Microenvironment to Ameliorate Mesenchymal Stromal Cell-Based Therapy in Chronic Lung Diseases.

Authors:  Linda Elowsson Rendin; Anna Löfdahl; Måns Kadefors; Zackarias Söderlund; Emil Tykesson; Sara Rolandsson Enes; Jenny Wigén; Gunilla Westergren-Thorsson
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

10.  Mesenchymal stromal cells reduce evidence of lung injury in patients with ARDS.

Authors:  Katherine D Wick; Aleksandra Leligdowicz; Hanjing Zhuo; Lorraine B Ware; Michael A Matthay
Journal:  JCI Insight       Date:  2021-06-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.